Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.67 USD | +3.03% | -2.90% | +30.66% |
Financials (USD)
Sales 2024 * | 98.05M | Sales 2025 * | 83.06M | Capitalization | 80.68M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -48M | EV / Sales 2024 * | 0.34 x |
Net cash position 2024 * | 47.51M | Net cash position 2025 * | 57.37M | EV / Sales 2025 * | 0.28 x |
P/E ratio 2024 * |
-0.84
x | P/E ratio 2025 * |
-1.93
x | Employees | 225 |
Yield 2024 * |
299% | Yield 2025 * |
299% | Free-Float | 97.23% |
Latest transcript on Atara Biotherapeutics, Inc.
1 day | +3.03% | ||
1 week | -2.90% | ||
Current month | -2.90% | ||
1 month | -13.98% | ||
3 months | -45.08% | ||
6 months | -48.06% | ||
Current year | +30.66% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Touchon
CEO | Chief Executive Officer | 61 | 19-06-23 |
Eric Hyllengren
DFI | Director of Finance/CFO | - | 17-12-31 |
Anhco Nguyen
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Gallagher
CHM | Chairman | 59 | 12-12-31 |
Eric Dobmeier
BRD | Director/Board Member | 55 | 15-03-25 |
William Heiden
BRD | Director/Board Member | 64 | 15-11-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 0.67 | +3.03% | 741,816 |
24-05-02 | 0.6503 | -5.00% | 2,214,549 |
24-05-01 | 0.6845 | -0.80% | 1,117,460 |
24-04-30 | 0.69 | -3.39% | 707,756 |
24-04-29 | 0.7142 | +3.51% | 999,999 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.66% | 80.68M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- ATRA Stock